(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 November 2015 (26.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/179724 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/712* (2006.01)
A61P 9/00 (2006.01)

(21) International Application Number:
PCT/US2015/032099

(22) International Filing Date:
22 May 2015 (22.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/001,731 22 May 2014 (22.05.2014) US
62/047,978 9 September 2014 (09.09.2014) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **FOSTER, Donald**; 300 Third Street, Cambridge, MA 02142 (US). **BETTENCOURT, Brian**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **CHARISSE, Klaus**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **HINKLE, Gregory**; 300 Third Street, Cambridge, MA 02142 (US). **KUCHIMANCHI, Satyanarayana**; 300 Third Street, 3rd Floor, Cambridge, MA (US). **MAIER, Martin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MILSTEIN, Stuart**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(74) Agents: **ZACHARAKIS, Maria, Laccotripe** et al.; Mccarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

(54) Title: ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to RNAi agents, e.g., double- stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.




Figure 1

WO 2015/179724 A1

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*